Biotech flotations offer venture funds an accelerating exit
Start-ups floated faster than usual in 2020, a new analysis finds. For a deeper look at biopharma deal trends, our free report is available to download today.
Ortho Clinical takes a haircut
Discount pricing and poor first day defies the recent trend for floating device makers.
Astounding success greets newly public device makers
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
After a big year, biotech flotations have much to do
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
What the coming year might hold for biopharma
Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
Mapping the transatlantic divide for biotech flotations
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Hints of moderation emerge in biotech venture funding
Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.
Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Another huge quarter for biotech flotations
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.
